To include your compound in the COVID-19 Resource Center, submit it here.

U.K. unveils second life sciences deal, headlined by UCB investment

Just days ahead of a Parliamentary vote on a Brexit deal, the U.K. government announced Wednesday a second deal for life sciences that comprises mostly industry investment into the U.K. spearheaded by a £1 billion ($1.3 billion) investment by Belgian pharma UCB S.A. (Euronext:UCB) over the next five years.

Read the full 491 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers